Immuron (NASDAQ:IMRN – Get Free Report) is expected to issue its results before the market opens on Friday, August 28th. Analysts expect Immuron to announce earnings of ($0.0037) per share and revenue of $2.7450 million for the quarter.
Immuron Stock Performance
Immuron stock opened at $1.14 on Thursday. Immuron has a 12 month low of $0.68 and a 12 month high of $2.39. The business has a 50 day simple moving average of $1.13 and a 200-day simple moving average of $0.98.
Analyst Ratings Changes
Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of Immuron in a research note on Wednesday, June 24th. One research analyst has rated the stock with a Sell rating, Based on data from MarketBeat, the company has an average rating of “Sell”.
Institutional Investors Weigh In On Immuron
A hedge fund recently bought a new position in Immuron stock. Citadel Advisors LLC bought a new stake in shares of Immuron (NASDAQ:IMRN – Free Report) in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 19,562 shares of the company’s stock, valued at approximately $37,000. Citadel Advisors LLC owned about 0.29% of Immuron at the end of the most recent reporting period. Institutional investors own 0.12% of the company’s stock.
Immuron Company Profile
Immuron Limited, a biopharmaceutical company, researches and develops oral immunotherapy polyclonal antibodies for the treatment and prevention of infectious and immune modulated diseases in Australia, the United States, and internationally. The company operates through two segments, Research and Development, and Hyperimmune Products. The company markets Travelan and Protectyn for the prevention of travellers' diarrhea. Its lead product candidates include IMM-124E that is in Phase II clinical trials for non-alcoholic steatohepatitis, severe alcoholic hepatitis, and non-alcoholic fatty liver disease, as well as used in antiviral activity against the COVID-19 virus in laboratory studies; and IMM-529, a clinical stage product for clostridium difficile infections.
See Also
- Five stocks we like better than Immuron
- Williams-Sonoma’s Quarter Gave Bulls More Than Just a Beat-and-Raise
- Alcoa’s Gallium Project Opens a New Door Beyond Aluminum
- Oura’s $16 Billion IPO Could Put a New Price on Wearable Tech
- Can Tesla’s Flying Roadster Distract From Its Real Risks?
Receive News & Ratings for Immuron Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immuron and related companies with MarketBeat.com's FREE daily email newsletter.
